Research
Hormonal
There has been a shift in the therapeutic approach to coronary artery disease (CAD) in patients with Type 2 Diabetes Mellitus (T2DM).
Healthcare providers should stay updated on evolving treatment strategies for CAD in T2DM patients.
StrongSupportsmedium confidence
Over recent years, there has been a shift in the therapeutic approach to CAD, especially in T2DM patients.
Why this rating
The abstract discusses recent developments in treatment approaches.
Source
Cardiovascular Protection in Coronary Artery Disease: Mechanistic and Clinical Insights into SGLT2 Inhibitors and GLP-1 Receptor Agonists
Nicola Cosentino et al. · Pharmaceuticals · 2025
DOI 10.3390/ph18081202
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate notable cardiovascular benefits beyond glucose regulation in patients with coronary artery disease (CAD).Strong
- The interaction between hyperglycemia, endothelial dysfunction, inflammation, and thrombosis contributes to the progression of coronary artery disease (CAD) and its acute complications.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →